Skip to main content

An official website of the United States government

You have 2 new alerts

MEX-AD:Clinical, epidemiological, & genetic characterization of Alzheimer's patients in the admixed Mexican population

info alert

Note: There have been new actions to this contract opportunity. To view the most recent action, please click here.

Looking for contract opportunity help?

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information

  • Contract Opportunity Type: Solicitation (Updated)
  • Updated Published Date: Jan 12, 2024 04:03 pm EST
  • Original Published Date: Jan 12, 2024 02:50 pm EST
  • Updated Date Offers Due: Feb 26, 2024 11:00 am EST
  • Original Date Offers Due: Feb 26, 2024 11:00 am EST
  • Inactive Policy: 15 days after date offers due
  • Updated Inactive Date: Mar 12, 2024
  • Original Inactive Date: Mar 12, 2024
  • Initiative:
    • None

Classification

  • Original Set Aside:
  • Product Service Code: AN41 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
  • NAICS Code:
    • 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
  • Place of Performance:
    MEX

Description

The purpose of this requirement is to establish a multicentre cohort study in Mexico and characterize Alzheimer's
disease (AD) patients' clinical, genetic, and phenotypic diversity in the admixed Mexican population, a group with
unique genetic admixture and environmental exposures that is underrepresented in AD research.

First, the Contractor shall determine the genetic substructure and familial contributions to AD in Mexico. This will
advance efforts to treat AD in patients with rare mutations.

Second, by assembling this large cohort, the Contractor shall work to establish a preliminary Mexican-specific
polygenic risk score (PRS) for predicting AD risk in future samples.

Please see attached RFP titled "75N95024R00016 Solicitation" for the full solicitation.

Contact Information

Contracting Office Address

  • c/o 3WFN MSC 6012 301 N Stonestreet Ave
  • Bethesda , MD 20892
  • USA

Primary Point of Contact

Secondary Point of Contact

History